CERo Therapeutics Holdings, Inc. (CERO) stock
Close on Oct 19, 2026Market cap $253.05KP/E –Yield 172833.33%
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $253.05K
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- 172833.33%
- Free cash flow yield
- –
Fundamentals
- Net income
- -$16.31M
- Book value per share
- -$0.72
- Diluted shares
- 42M
Trading
- Previous close
- $0.01
- Open
- $0.01
- Day's range
- $0.01 – $0.01
- Volume
- 234,796
- Average volume (20 days)
- 731,067
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | CERO | S&P 500 | Difference | CERO per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -41.2% | +0.6% | −41.8 pts | ||
| 3 months | -45.5% | +3.4% | −48.8 pts | ||
| Year to date | -91.0% | +13.3% | −104.3 pts | ||
| 1 year | -99.7% | +16.6% | −116.3 pts | ||
| 3 years | -100.0% | +86.4% | −186.4 pts | -99.3% | +23.1% |
Five years at a glance
Fiscal years 2021 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Press releases
Releases CERo Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- News
- Update
- Update
- News
- Update
- News
About CERo Therapeutics
Biological Products, (No Diagnostic Substances)
CERo Therapeutics Holdings, Inc. is a clinical-stage biotechnology company focused on developing genetically engineered cellular immunotherapies for cancer treatment. The company designs Chimeric Engulfment Receptor T cell therapies, known as CER-T cells, which integrate characteristics of innate and adaptive immune responses to target and eliminate cancer cells. Its primary product candidate in development is CER-1236. Because its candidate therapies remain in early clinical or preclinical stages, the company has not yet commercialized any therapies, meaning its potential future customers will consist of cancer patients and healthcare providers upon regulatory approval.
Company profile, executives and historyCERo Therapeutics stock: common questions
What is CERo Therapeutics's stock price?
CERO closed at $0.01 on Oct 19, 2026, up 0.00% on the day.
What is CERo Therapeutics's market cap?
CERo Therapeutics was worth $253.05K at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
Does CERo Therapeutics pay a dividend?
Yes. CERo Therapeutics paid $10.37 per share over the last twelve months, a yield of 172833.33% at the latest price.
How has CERO stock performed over the past year?
Including dividends, CERO returned -99.7% over the past year, against +16.6% for the S&P 500.
Who are CERo Therapeutics's competitors?
Companies most similar to CERo Therapeutics by business, industry and size include INAB, CLDI, CPMV, RVMD, ESLA.
See a number that looks wrong?